Pemvidutide
Pemvidutide is an experimental dual GLP-1/glucagon receptor agonist for the treatment of MASH, obesity, AUD, and ALD developed by Altimmune, a clinical-stage biopharmaceutical company based in Gaithersburg, Maryland.
The drug reduced LDL-C in a clinical trial and does not require dose titration as with GLP-1 mono agonists. The company's latest Phase 2 trial also showed improvement in MASH combined with significant weight loss.